Literature DB >> 27464947

Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.

Hiroshi Yamazaki1, Hiroshi Suemizu2, Yasuhiro Kazuki3, Ken Oofusa4, Shunji Kuribayashi5, Makiko Shimizu1, Shinichi Ninomiya6, Toru Horie7, Norio Shibata8, F Peter Guengerich9.   

Abstract

Bioactivation of 5-hydroxy-[carbonyl-(14)C]thalidomide, a known metabolite of thalidomide, by human artificial or native cytochrome P450 3A enzymes, and nonspecific binding in livers of mice was assessed using two-dimensional electrophoresis combined with accelerator mass spectrometry. The apparent major target proteins were liver microsomal cytochrome c oxidase subunit 6B1 and ATP synthase subunit α in mice containing humanized P450 3A genes or transplanted humanized liver. Liver cytosolic retinal dehydrogenase 1 and glutathione transferase A1 were targets in humanized mice with P450 3A and hepatocytes, respectively. 5-Hydroxythalidomide is bioactivated by human P450 3A enzymes and trapped with proteins nonspecifically in humanized mice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27464947      PMCID: PMC5282975          DOI: 10.1021/acs.chemrestox.6b00210

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  18 in total

1.  In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Makiko Shimizu; Sho Igaya; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-01-25       Impact factor: 3.739

2.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

3.  A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease.

Authors:  Gen Tamiya; Satoshi Makino; Makiko Hayashi; Akiko Abe; Chikahiko Numakura; Masao Ueki; Atsushi Tanaka; Chizuru Ito; Kiyotaka Toshimori; Nobuhiro Ogawa; Tomoya Terashima; Hiroshi Maegawa; Daijiro Yanagisawa; Ikuo Tooyama; Masayoshi Tada; Osamu Onodera; Kiyoshi Hayasaka
Journal:  Am J Hum Genet       Date:  2014-08-21       Impact factor: 11.025

4.  The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.

Authors:  Masami Hasegawa; Kenji Kawai; Tetsuya Mitsui; Kenji Taniguchi; Makoto Monnai; Masatoshi Wakui; Mamoru Ito; Makoto Suematsu; Gary Peltz; Masato Nakamura; Hiroshi Suemizu
Journal:  Biochem Biophys Res Commun       Date:  2011-01-14       Impact factor: 3.575

5.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

6.  Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans.

Authors:  Yasuhiro Kazuki; Kaoru Kobayashi; Sasitorn Aueviriyavit; Takeshi Oshima; Yoshimi Kuroiwa; Yasuko Tsukazaki; Naoto Senda; Hiroki Kawakami; Sumio Ohtsuki; Satoshi Abe; Masato Takiguchi; Hidetoshi Hoshiya; Naoyo Kajitani; Shoko Takehara; Kinya Kubo; Tetsuya Terasaki; Kan Chiba; Kazuma Tomizuka; Mitsuo Oshimura
Journal:  Hum Mol Genet       Date:  2012-11-02       Impact factor: 6.150

7.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

8.  STRING v10: protein-protein interaction networks, integrated over the tree of life.

Authors:  Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2014-10-28       Impact factor: 16.971

9.  Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Authors:  Yasuhiro Kazuki; Masaharu Akita; Kaoru Kobayashi; Mitsuhiko Osaki; Daisuke Satoh; Ryo Ohta; Satoshi Abe; Shoko Takehara; Kanako Kazuki; Hiroshi Yamazaki; Tetsuya Kamataki; Mitsuo Oshimura
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

10.  Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells.

Authors:  Kesavan Meganathan; Smita Jagtap; Vilas Wagh; Johannes Winkler; John Antonydas Gaspar; Diana Hildebrand; Maria Trusch; Karola Lehmann; Jürgen Hescheler; Hartmut Schlüter; Agapios Sachinidis
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more
  5 in total

1.  Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.

Authors:  Makiko Shimizu; Hiroshi Suemizu; Marina Mitsui; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Xenobiotica       Date:  2016-11-16       Impact factor: 1.908

2.  Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.

Authors:  Norie Murayama; Yasuhiro Kazuki; Daisuke Satoh; Kazuya Arata; Tasuku Harada; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2017       Impact factor: 2.196

3.  Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.

Authors:  Norie Murayama; Hiroshi Suemizu; Shotaro Uehara; Takashi Kusama; Marina Mitsui; Yusuke Kamiya; Makiko Shimizu; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2018       Impact factor: 2.196

4.  Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors:  Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

5.  Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.

Authors:  Shaunna L Beedie; Phoebe A Huang; Emily M Harris; Jonathan D Strope; Christopher Mahony; Cindy H Chau; Neil Vargesson; William D Figg
Journal:  FASEB J       Date:  2020-07-17       Impact factor: 5.834

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.